Cambridge Healthtech Institute’s Inaugural

Process Optimisation for Cultivated Meat

New Technologies and Strategies to Optimize Manufacturing Steps and Reduce Production Costs

19 - 20 March 2024 ALL TIMES CET

We have added a new Alternative Protein Production stream to Bioprocessing Summit Europe to recognize the synergies between the manufacturing technologies used for these nascent food products and biologic drugs. This meeting provides an opportunity for these communities to share best practices and explore prospects for collaborations and technological innovations. The first 1.5-day program, Process Optimisation for Cultivated Meat, explores advances in cell line development and cell culture, innovative approaches to upstream processing, and in-process strategies for improving product control. Additionally, updates on regulatory and cultural impacts affecting the field will be discussed. Speakers and delegates participating in this track may also attend talks in six other programming streams at the event.

Tuesday, 19 March

Registration and Morning Coffee07:00

CELL LINE DEVELOPMENT

08:55

Chairperson's Remarks

Michael Sulu, PhD, Lecturer, Biochemical Engineering; Senior Fellow, Higher Education Academy (SFHEA), University College London

09:00

Cultivated Pork on Microalgae Base

Vladislav Strmiska, PhD, Senior Scientist, Mewery

Cultivated pork meat in multi-organism combination is a challenging hybrid technological process which pays off. Microalgae, as the key substrate in a process of porcine cells cultivation, are used for three separate platforms: for FBS replacement, as microcarrier, and for growth factors production.

  • Microalgal cocktail is crucial media component to replace FBS for sustainable and animal free meat production. 
  • Live microalgae in co-cultivation with porcine cells act as microcarrier in scaffolding hybrid biomass in 3D structure.
  • Growth factors produced under microalgae cultivation conditions allow to simplify porcine cells growth media composition without recombinant protein purification and concentration. 
09:30

Developing a Scalable Process for Cultivated Meat Production Begins with High-Quality Cells

Jef Pinxteren, Vice President, Development, Roslin Technologies Limited

Roslin Technologies is a pioneer in pluripotent stem cell development for cultivated meat applications. Our multi-species, indefinitely self-renewing, karyotypically-normal stem cells are developed from elite animal breeding stocks and supplied with full traceability and data-supporting cultivated meat regulatory dossiers. We share our latest bioprocess metrics supporting the development of robust, scalable cultivated meat production solutions.

Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing10:00

UPSTREAM PROCESSING

10:45

Challenges and Opportunities in Upstream Processing

Michael Sulu, PhD, Lecturer, Biochemical Engineering; Senior Fellow, Higher Education Academy (SFHEA), University College London

This talk will set out the challenges and opportunities in upstream processing for alternative protein production. It will seek to identify knowledge- and-skills gaps in the domain, as well as what can be learnt from the various sectors of biotechnology (the intersections with Red, White, Green, Blue and Gold Biotech), and conclude by circling back to the gaps to identify areas that could provide the greatest opportunities in the research and industrial environment.

11:15

Media Optimisation Strategies: Peeling Off the Levels of Uncertainty

Aleksandra Fuchs, PhD, Senior Scientist, Austrian Centre of Industrial Biotechnology

Media optimization strategies have evolved significantly in recent decades, benefiting from recent advances in various interdisciplinary fields. These encompass a broader comprehension of cellular processes, AI-driven protein design, simulation of protein-protein interactions, experimental design, and omics-based modelling of cellular processes within digital twins. When sequentially applied, these approaches not only deepen our understanding of the processes, but also improve the predictability of the system, ultimately resulting in superior performance.

  • Recent advances in various interdisciplinary fields promote significant progress in medium optimization strategies
  • AI-driven protein design and simulation of protein-protein interactions allow prediction of growth factor behaviour
  • New design of experiment schemes and omics-based modelling of cellular processes within digital twins
11:45

Computer-Aided Design and Computational Fluid Dynamics Software for Bioreactor Design

Akin Odeleye, PhD, Head, Bioprocessing, Ivy Farm Technologies

Computer-aided design (CAD) and computational fluid dynamics (CFD) are playing key roles in the digital transformation of bioprocesses. CAD and CFD can be used to enable scale-up, predicting performance of lab- and production-scale reactors. Such models also play a key role in bioreactor design, augmenting our control over the fluid dynamic environment.

12:15 Cost Efficient Cultivated Meat Production Through Deeper Process Insights

Yavuz Çelik, Product Manager, Process Analytics, Hamilton Bonaduz AG

Explore efficiency and cost-saving strategies in cultivated meat processes using process analytics. This presentation highlights how Hamilton sensors address cultivated meat production challenges, ensuring improved process control and optimization through inline, real-time measurements. Gain insights into critical process parameters and KPIs essential for optimal product growth and yield. Understand how controlling these parameters can significantly reduce process costs and downtime.

Networking Lunch (Sponsorship Opportunity Available)12:30

SCALE-UP AND PROCESS SYSTEMS ENGINEERING

14:15

Chairperson's Remarks

Michael Sulu, PhD, Lecturer, Biochemical Engineering; Senior Fellow, Higher Education Academy (SFHEA), University College London

14:20

From Cell to Tissue Processing—Enabling Cultivated Meat Production at-Scale

Barak Zohar, PhD, CTO, Ever After Foods

Traditional cell processing systems such as stirred tank bioreactor fail to provide the conditions for growing tissues at-scale. We developed a proprietary scalable packed-bed bioreactor technology consist of plant based edible scaffolds for growing tissues in extremely high productivity. Our technology can increase the production yield of cultivated meat 13-fold and reduce the cost of production in more than 90%. Our current 35-liter pilot scale bioreactor can yield more than 10Kg of cultivated meat per run. Going forward, our 1,400-liter production system will yield more than 400Kg cultivated meat per run.

14:50

FEATURED PRESENTATION: Bioprocess Intensification Strategy for Cultivated Meat Production

Petra Hanga, PhD, Lecturer, Biochemical Engineering and Cellular Agriculture, University College London

We have developed a scalable, microcarrier based, intensified bioprocess for the expansion of bovine adipose‐derived stem cells as precursors of fat, a component of cultivated meat, first in spinner flasks of different sizes and then translated to fully controlled litre scale benchtop bioreactors. Bioprocess intensification utilised the bead‐to‐bead transfer phenomenon and the combined addition of microcarrier and medium to double the existing surface area and working volume in the bioreactor.

Refreshment Break in the Exhibit Hall with Poster Viewing15:20

16:20

Scale-Up of the Cocoon Protein Expression Platform

Romy Moreno Dalton, PhD, COO, Cocoon Bioscience

Cocoon Bioscience has developed an automated, baculovirus-based platform that utilises living insects in their chrysalis state as natural bioreactors for producing complex recombinant proteins with high activity that are difficult or impossible to produce in traditional expression systems. Initially developed for production of vaccines at a gram-scale, Cocoon is currently scaling the technology—on upstream, downstream, and starting material input—to the gram-scale at an industrial facility

16:50

Scaling-Up Strategies for Cell-Cultured Seafood

Keerthi Srinivas, PhD, Director, Bioprocess Development, Bluenalu

Scaling-up cell culture requires understanding and improving cell kinetics, bioreactor hydrodynamics, and substrate/nutrient feeding strategies, using process analytics, empirical kinetic & mechanistic modelling, and effective bioreactor designs. This presentation will focus on implementing effective scaling techniques in suspension cell culture for accelerating delivery of high-quality, delicious seafood to market, and advancing sustainability in our food system. 

17:20

Prospects for Producing Cultured Meat at a Farm: Scale-Up Strategy and Realisation Aspects

Charilaos Korkontzelos, Bioprocess Scientist, RESPECTfarms

Ira van Eelen, PhD, Co-Founder, RESPECTfarms

Single-use bioreactors, originally designed for biopharmaceutical processes, can serve as a basis for a dedicated process design for a farm-scale operation for cultured meat production. Single-use bioreactors available today may not fully address the capacity needs of cultured meat production, but due to their flexibility, scale-out is possible, and application of such reactor types makes the seeding steps of these processes more flexible and more reliable in terms of sterility, which is an important aspect for successful operation at a farm.

  • Farm-scale production of cultured meat
  • Application single-use bioreactors
  • Scale-up by scale-out

INTERACTIVE BREAKOUT DISCUSSIONS

17:50Interactive Breakout Discussions

Interactive Breakout Discussions are informal, moderated discussions, allowing participants to exchange ideas and experiences and develop future collaborations around a focused topic. Each discussion will be led by a facilitator who keeps the discussion on track and the group engaged. To get the most out of this format, please come prepared to share examples from your work, be a part of a collective, problem-solving session, and participate in active idea sharing. Please visit the Interactive Breakout Discussions page on the conference website for a complete listing of topics and descriptions.

IN-PERSON ONLY BREAKOUT:

Technological Hurdles Cultivated Meat Still Needs to Master

Aleksandra Fuchs, PhD, Senior Scientist, Austrian Centre of Industrial Biotechnology

  • Cell culture medium - is there still a potential for lowering the price?
  • Do we expect a breakthrough in bioreactor design?
  • What is the potential of computational approach/AI in mastering these hurdles?​

Welcome Reception in the Exhibit Hall with Poster Viewing18:30

Close of Day19:30

Wednesday, 20 March

Registration and Morning Coffee08:00

TRENDS, CHALLENGES, AND OPPORTUNITIES

08:55

Chairperson's Remarks

Christoph Herwig, PhD, former Professor, Bioprocess Engineering, Vienna University of Technology; CPO, Fermify GmbH; Senior Scientific Advisor, Körber Pharma Austria

09:00

FEATURED PRESENTATION: Cultivated Meat in Europe: Major Trends and Opportunities

Seren Kell, Senior Science and Technology Manager, The Good Food Institute Europe

This talk will cover the growing need for transforming our global food system in order to sustainably feed the world by 2050, introducing the role that cultivated meat can play in this transition. It will also overview the present commercial, investment, and socio-political landscape in Europe, as well as the scientific and industrial challenges presently preventing cultivated meat from achieving large-scale market uptake. Finally, it will outline the opportunities for researchers and scientists from multiple disciplines to help to tackle these challenges, and how they can contribute towards this flourishing global research community.

09:30

Navigating Regulatory and Quality Challenges in Europe and Beyond

Hannah Lester, PhD, CEO & Principal Consultant, Atova Consulting

This presentation explores the intricate landscape of cultivated meat regulation and quality standards in Europe and global markets. We will delve into the dynamic legal framework, addressing hurdles and opportunities for industry players. By examining key quality assurance strategies, this session equips stakeholders with insights to navigate evolving landscapes, and ensure safe, sustainable, and delicious cultured meat products for consumers.

10:00

Sustainability and Innovation in Production Economics

Stefano Lattanzi, PhD, CEO, BrunoCell

Cultivated meat is a disruptive technology and an anthropological revolution. News in the media suggests the field is at an advanced technology readiness level (TRL), ready to hit the market at scale. But, with current manufacturing processes, cultured meat is still extremely expensive and faces a challenging route to scaling up.  Also, resistance to governmental regulation from the traditional meat sector is rising, and in Italy this took the form of a controversial ban. With the perspective of an insider in this field since 2009, we describe promises and challenges of this field.

Coffee Break in the Exhibit Hall with Poster Viewing10:30

PLENARY KEYNOTE SESSION

BACK TO THE FUTURE OF BIOPROCESSING—ANTIBODIES TO EXTRACELLULAR VESICLES

11:15

Chairperson's Opening Remarks

Alois Jungbauer, PhD, Professor & Head, Biotechnology, Institute of Bioprocess Science and Engineering, University of Natural Resources and Life Sciences (BOKU)

11:20 PLENARY PRESENTATION:

What Have Monoclonal Antibodies Ever Done for Us? Past, Present, and Future Perspectives on Antibodies and How They Have Driven Bioprocessing Progress

Paul Varley, PhD, Senior Vice President, Development, Alchemab Therapeutics

Advances in bioprocessing have been pivotal to the emergence of monoclonal antibodies as one of the most successful classes of drugs in modern medicine. In this talk we will consider this journey and ask what's next for antibodies. We will also explore how advances in antibody bioprocessing continue to enable the next generation of biological medicines through the emergence of new product modalities.

11:50 PLENARY PRESENTATION:

Extracellular Vesicles as Promising Drug Modalities in Spinal Cord Injury and Other (Neuro-)Degenerative Diseases

Eva Rohde, MD, Chair, Transfusion Medicine, Director GMP Unit, Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University Salzburg

Extracellular vesicles (EVs) have emerged as promising new biologic drug modalities. EV therapeutics (EV-Tx) from mesenchymal stromal cells (MSC) exert anti-inflammatory, anti-fibrotic and regenerative effects. MSC-EV-Tx could optimise healing after acute traumatic injury. Challenges in reproducible EV-Tx manufacturing prevent comprehensive evaluation of their efficacy. In early research, the paradigm of “the-process-is-the-product” is valid for complex biologicals. A “one-size-fits-all” approach to solve technical and regulatory issues is not available for EV-Tx. The claimed disease-related mechanisms of action (MoA) of candidate EV-Tx will determine regulatory requirements to be met. This presentation will introduce concepts to accelerate EV-Tx testing in various target diseases.

Session Break12:20

Networking Lunch (Sponsored Opportunity Available)12:35

Close of Process Optimisation for Cultivated Meat Conference14:05